StreetAlpha.app
Home › Stocks › IMMX

Immix Biopharma, Inc. (IMMX)

Healthcare
$7.20
▼ −3.74%
LAST CLOSE · NOV 17

Immix Biopharma develops CAR T cell therapies, led by NXC-201, for AL amyloidosis and other serious diseases. It last closed at $7.20 on Nov 17, down 3.74% on the day. The average 12-month price target from 3 analysts is $27.67 (+284.3% from the last close), with a high of $30.00 and a low of $26.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is IMMX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$46.2M
EPS (diluted)
−$0.83
Free cash flow
−$45.2M
Valuation
Market cap
$603.4M
83.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$320.3M
At Sep 30
Shareholder equity
$335.1M
Shares outstanding
83.8M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$24.4M−$24.4MFY2021FY2022: −$8.2M−$8.2MFY2022FY2023: −$15.4M−$15.4MFY2023FY2024: −$21.6M−$21.6MFY2024FY2025: −$29.4M−$29.4MFY2025

From IMMX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on IMMX in the past 90 days
Average 12-month target
$27.67
▲ 284.3% upside

Based on 3 analysts who set a price target on IMMX in the past 90 days. The average target is $27.67, with a high of $30.00 and a low of $26.00, compared with the last close of $7.20.

Low $26.00Avg $27.67High $30.00
Blue marker: last close $7.20
Highest target$30.00
Average target$27.67
Lowest target$26.00
Latest rating changes
HC Wainwright & Co.Target raised
Nov 16Buy$25 → $27
NeedhamTarget raised
Sep 29Buy$21 → $30
MizuhoMaintained
Sep 15Buy$26
Morgan StanleyMaintained
Aug 11Buy$19
HC Wainwright & Co.Target raised
Aug 10Buy$20 → $25
DateFirmActionRatingPrice target
Nov 16HC Wainwright & Co.Target raisedBuy$25 → $27
Sep 29NeedhamTarget raisedBuy$21 → $30
Sep 15MizuhoMaintainedBuy$26
Aug 11Morgan StanleyMaintainedBuy$19
Aug 10HC Wainwright & Co.Target raisedBuy$20 → $25
Loading…

Technical Analysis

IMMX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 11% below its 20 day and 33% below its 50 day average. It is 34% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 37), near oversold. The nearest support is the swing low (Nov 5) at $7.12, and the nearest resistance the Pivot at $7.29.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNear oversold
VolatilityNormal, 8.8%/day
Key levels
$15.1052 week high+109.7%
$10.33100 day average+43.5%
$9.63200 day average+33.8%
$9.5750 day average+32.9%
$8.36Swing high (Oct 29)+16.1%
$7.9620 day average+10.6%
$7.45Pivot R1+3.5%
$7.29Pivot+1.2%
$7.20Last close
$7.12Swing low (Nov 5)−1.1%
$7.04Pivot S1−2.2%
$3.7852 week low−47.5%
Indicators
RSI (14)37.44Weak, oversold below 30Neutral
MACD-0.47Above its signal lineBullish
Stochastic21.9Middle of its rangeNeutral
ADX (14)32.7Trending down
Williams %R-95.5Oversold below −80, overbought above −20Oversold
CCI (20)-146.8Oversold below −100, overbought above 100Oversold
Rate of change−6.6%Change over 10 sessionsBearish
ATR (14)$0.63Typical daily range, 8.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMMX

What happened before

See how IMMX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IMMX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IMMX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IMMX in the last 90 days.

Loading…

See today’s whale options flow across the market →

IMMX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲103 buying vs 32 selling
  • ▲Held by funds +11.5 pts
  • ▲Funds holding +28
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding137109+25.7%
In funds' top 1043+33.3%
Held by funds78.6%67.1%+11.5 pts
New / increased41 / 6243 / 34+33.8%
Reduced / sold out19 / 1313 / 11+33.3%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMMX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMMX is in one of them and how their past IMMX trades turned out.

IMMX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMMX in an article yet. Here's the latest on the wider market.

About Immix Biopharma

Immix Biopharma is a biopharmaceutical company based in Los Angeles, California. It develops chimeric antigen receptor (CAR) T cell therapies, led by its candidate NXC-201, for AL amyloidosis, a serious disease in which an abnormal protein builds up in organs such as the heart and kidneys. The lead candidate is in clinical trials and is not yet approved for sale. The company's target patients have this disease or other serious conditions where CAR T therapy is not yet an approved treatment.

Headquarters
Los Angeles, CA